Mallinckrodt Files 2025 Proxy Statement
| Field | Detail |
|---|---|
| Company | Mallinckrodt PLC |
| Form Type | DEF 14A |
| Filed Date | Apr 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Mallinckrodt's proxy statement is in, shareholders vote soon on company matters.
AI Summary
Mallinckrodt plc filed its definitive proxy statement (DEF 14A) on April 3, 2025, for its annual meeting on May 15, 2025. The filing concerns the company's governance and shareholder matters. Mallinckrodt is a global biopharmaceutical company focused on specialty brands and specialty generics.
Why It Matters
This filing provides shareholders with crucial information regarding the company's leadership, executive compensation, and voting matters, enabling informed participation in corporate decisions.
Risk Assessment
Risk Level: low — This is a routine proxy filing providing information to shareholders, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 20250403 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 20250515 — Meeting Date (Date of the shareholder meeting for which this proxy statement is issued.)
Key Players & Entities
- Mallinckrodt plc (company) — Registrant
- 0001104659-25-031453.txt (document) — Accession Number
- 20250403 (date) — Filing Date
- 20250515 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is used by companies to solicit proxy votes from shareholders for an upcoming shareholder meeting.
When was Mallinckrodt's definitive proxy statement filed?
Mallinckrodt's definitive proxy statement was filed on April 3, 2025.
What is the date of the shareholder meeting Mallinckrodt is soliciting proxies for?
The shareholder meeting for which Mallinckrodt is soliciting proxies is scheduled for May 15, 2025.
What is Mallinckrodt's primary business?
Mallinckrodt is a global biopharmaceutical company focused on specialty brands and specialty generics.
Is there a filing fee associated with this proxy statement?
No fee was required for this filing, as indicated by the 'No fee required' checkbox being selected.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 3, 2025 regarding Mallinckrodt plc.